These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 22678358)

  • 1. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia.
    Matsuoka A; Takahashi N; Miura M; Niioka T; Kawakami K; Matsunaga T; Sawada K
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):351-2. PubMed ID: 22678358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
    Takahashi N; Miura M; Niioka T; Sawada K
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Keam SJ
    BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
    Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
    J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
    Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
    Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.
    Wong SF
    J Oncol Pharm Pract; 2009 Mar; 15(1):17-27. PubMed ID: 18753186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
    Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Fujii Y; Amano M; Seriu T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
    Pang J; Dalziel G; Dean B; Ware JA; Salphati L
    Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biopharmaceutical studies of JLTN as potential dasatinib prodrug.
    Liu F; Lang LW; Jiang J; Lu HJ; Wang JM; Wang SC
    Chem Pharm Bull (Tokyo); 2013; 61(8):877-81. PubMed ID: 23676628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
    Koutake Y; Taniguchi J; Yasumori N; Nagaishi H; Eto T; Nakashima K; Fukazawa M; Hayashi T
    Int J Hematol; 2020 Jun; 111(6):826-832. PubMed ID: 32152877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
    Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
    Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
    Tyler T
    Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.